Matthew Harrison

Q: What is Matthew Harrison's success rate?

Matthew Harrison currently has a success rate of 88.09223390708799.

Q: What is the average return of Matthew Harrison's calls?

Their stock ratings have generated an average return of 18.98567406672479.

Morgan Stanley | Healthcare

Matthew Harrison is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1413 out of 4639 analysts, they have issued 41 stock ratings with a success rate of 88.09% and an average return of 18.99%.

Matthew Harrison has a well-established track record, with 41 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 88.09% and an average return of 18.99%, underscoring their expertise and ability to identify winning opportunities for investors.

#1413

Out of 4639

Total Ratings

+88.09%

Success Rate

+18.99%

Average Return

Recent Ratings Analysis

BIIB

Hold

Apr 30, 2026

Target

$206.00

Current

$187.21

Performance

-1.09%

Matthew Harrison rated BIIB as Equal-Weight on Apr 30, 2026, setting a price target of 206. The Hold stance appears justified, as shares hovered around 187.21 with a -1.09% move.

REGN

Hold

Apr 10, 2026

Target

$796.00

Current

$709.21

Performance

-5.30%

On Apr 10, 2026, REGN was given a Equal-Weight rating by Matthew Harrison, with a target price of 796. The rating provided protection from downside risk as the stock fell to 709.21.

GILD

Buy

Apr 10, 2026

Target

$175.00

Current

$132.69

Performance

-4.53%

GILD received a Overweight rating from Matthew Harrison on Apr 10, 2026, aiming for 175. Price action was muted, as shares hovered around 132.69 despite the bullish outlook.

INSM

Buy

Mar 30, 2026

Target

$212.00

Current

$140.01

Performance

-8.68%

On Mar 30, 2026, Matthew Harrison published a Overweight outlook on INSM, with a target of 212. Market action contradicted the Buy thesis, as shares slipped to 140.01.

DNLI

Buy

Mar 26, 2026

Target

$42.00

Current

$18.67

Performance

—

Matthew Harrison on Mar 26, 2026 assigned DNLI a Overweight rating, with a price target of 42. The recommendation remains pending validation as shares consolidate around 18.67.

LEGN

Buy

Mar 11, 2026

Target

$50.00

Current

$26.50

Performance

30.74%

On Mar 11, 2026, Matthew Harrison reaffirmed LEGN with a Overweight rating, targeting 50. The recommendation was supported by strong follow-through as the stock rose from 26.5 to 26.5.

R

Buy

Feb 13, 2026

Target

$250.00

Current

$232.97

Performance

8.98%

R was rated Positive by Matthew Harrison on Feb 13, 2026, with a price objective of 250. A bullish response from the market helped close the gap of 17.03 to the target.

MRNA

Hold

Dec 12, 2025

Target

$30.00

Current

$47.30

Performance

60.56%

On Dec 12, 2025, Matthew Harrison initiated coverage on MRNA with a Equal-Weight rating and target of 30. The Hold stance underestimated the stock’s strength as it gained 60.56%.

PHVS

Buy

Dec 04, 2025

Target

$41.00

Current

$30.02

Performance

8.41%

Matthew Harrison issued a Overweight recommendation for PHVS on Dec 04, 2025, price target set at 41. Investors following the Buy call captured upside momentum, with shares now at 30.02.

ARGX

Buy

Dec 04, 2025

Target

$1110.00

Current

$811.09

Performance

-11.45%

On Dec 04, 2025, ARGX was evaluated by Matthew Harrison, who gave a Overweight rating and target of 1110. Investors saw limited payoff as shares fell short of the 1110 target.

ZNTL

Hold

Nov 12, 2025

Target

$4.00

Current

$4.00

Performance

198.51%

Matthew Harrison rated ZNTL as Equal-Weight on Nov 12, 2025, setting a price target of 4. Despite the Hold call, shares climbed 198.51% to 4, revealing unexpected momentum.

BMRN

Buy

Oct 28, 2025

Target

$98.00

Current

$55.46

Performance

3.68%

On Oct 28, 2025, BMRN was given a Overweight rating by Matthew Harrison, with a target price of 98. The stock traded sideways with a 3.68% move, keeping the bullish thesis unresolved.

IOBT

Buy

Aug 12, 2025

Target

$4.00

Current

$0.01

Performance

-99.06%

IOBT received a Overweight rating from Matthew Harrison on Aug 12, 2025, aiming for 4. The rating hasn’t played out as hoped, with the stock trading 99.06% below expectations.

VRTX

Hold

Aug 05, 2025

Target

$439.00

Current

$429.85

Performance

14.63%

On Aug 05, 2025, Matthew Harrison published a Equal-Weight outlook on VRTX, with a target of 439. The Hold call missed some of the bullish momentum as shares advanced toward 439.

SRPT

Hold

Jul 29, 2025

Target

$20.00

Current

$22.04

Performance

39.23%

Matthew Harrison on Jul 29, 2025 assigned SRPT a Equal-Weight rating, with a price target of 20. Shares outperformed expectations, climbing 39.23% despite the neutral view.

TSVT

Hold

Mar 14, 2025

Target

$5.00

Current

$5.00

Performance

1.01%

On Mar 14, 2025, Matthew Harrison reaffirmed TSVT with a Equal-Weight rating, targeting 5. The neutral call matched muted market action of 1.01%.

TNYA

Buy

Mar 12, 2025

Target

$5.00

Current

$0.79

Performance

31.60%

TNYA was rated Overweight by Matthew Harrison on Mar 12, 2025, with a price objective of 5. A bullish response from the market helped close the gap of 4.21 to the target.

LYV

Buy

Feb 21, 2025

Target

$178.00

Current

$157.58

Performance

5.48%

On Feb 21, 2025, Matthew Harrison initiated coverage on LYV with a Buy rating and target of 178. The stock’s climb of 5.48% since the call highlights the foresight in the rating.

AVNT

Buy

Feb 18, 2025

Target

$56.00

Current

$35.61

Performance

-19.45%

Matthew Harrison issued a Buy recommendation for AVNT on Feb 18, 2025, price target set at 56. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

CMCSA

Buy

Jan 31, 2025

Target

$55.00

Current

$27.07

Performance

-19.58%

On Jan 31, 2025, CMCSA was evaluated by Matthew Harrison, who gave a Buy rating and target of 55. Investors saw limited payoff as shares fell short of the 55 target.

ALEC

Sell

Nov 26, 2024

Target

$3.00

Current

$2.51

Performance

-2.33%

Matthew Harrison rated ALEC as Underweight on Nov 26, 2024, setting a price target of 3. So far, the bearish outlook hasn’t materialized, with shares flat near 2.51.

CNTA

Hold

Jun 21, 2024

Target

$11.00

Current

$39.70

Performance

336.26%

On Jun 21, 2024, CNTA was given a Equal-Weight rating by Matthew Harrison, with a target price of 11. The stock rallied from 39.7 to 39.7 after the Hold rating, surprising to the upside.

EDIT

Hold

May 09, 2024

Target

$7.00

Current

$3.00

Performance

-46.04%

EDIT received a Equal-Weight rating from Matthew Harrison on May 09, 2024, aiming for 7. The Hold stance proved prudent, with the market softening by 46.04%.

Frequency Asked Questions

Who is Matthew Harrison?

Matthew Harrison is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Matthew Harrison's success rate?

Matthew Harrison currently has a success rate of +88.09%.

How many ratings has Matthew Harrison issued?

Matthew Harrison has issued 41 stock ratings so far.

What is the average return of Matthew Harrison's calls?

Their stock ratings have generated an average return of +18.99%.

What is Matthew Harrison's ranking?

Matthew Harrison is ranked #1413 out of 4639 analysts.

What types of ratings does Matthew Harrison give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matthew Harrison?

You can follow Matthew Harrison by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matthew Harrison?

Their latest rating was a Hold on BIIB issued on 2026-04-30.